Last deal

$94M

Amount

Series A

Stage

15.02.2024

Date

1

all rounds

$94M

Total amount

General

About Company
Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Also Known As

FireFly

founded date

2022

Number of employees

Last funding type

Series A

IPO status

Private

Description

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.